Epigenomics (EPGNY) News Today → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free EPGNY Stock Alerts $2.39 0.00 (0.00%) (As of 04/6/2023) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEQS-News: Epigenomics AG publishes financial results for fiscal year 2023markets.businessinsider.com - March 14 at 7:22 AMEQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Boardmarkets.businessinsider.com - January 31 at 2:50 PMEQS-Adhoc: Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023markets.businessinsider.com - October 10 at 6:39 PMEQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023markets.businessinsider.com - October 10 at 6:39 PMCardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomicsfinance.yahoo.com - September 20 at 9:42 AMNew Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General Meetingbenzinga.com - September 14 at 3:37 PMEQS-News: Epigenomics AG publishes financial results for the first six months 2023markets.businessinsider.com - August 10 at 10:56 AMEQS-News: Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assetsmarkets.businessinsider.com - July 24 at 7:12 PMNew Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AGfinance.yahoo.com - July 24 at 2:12 PMEstimating The Intrinsic Value Of Epigenomics AG (ETR:ECX1)finance.yahoo.com - July 3 at 7:39 AMEpigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5 Mlnmarketwatch.com - June 12 at 6:18 PMEpigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resignsuk.news.yahoo.com - May 19 at 5:27 PMEQS-News: Epigenomics AG: Member of the Executive Board and Chief Scientific Officer Andrew Lukowiak Resignsmarkets.businessinsider.com - May 19 at 5:27 PMEpigenomics AG: Chief Executive Officer Greg Hamilton Resignsuk.finance.yahoo.com - April 13 at 8:13 AMEQS-Adhoc: Epigenomics AG: Changes in the Managementmarkets.businessinsider.com - April 12 at 6:34 PMEQS-News: Epigenomics AG: Chief Executive Officer Greg Hamilton Resignsmarkets.businessinsider.com - April 12 at 6:34 PMEpigenomics AG: Adjustment of guidance and notice of loss pursuant to sec. 92 para. 1 of the German Stock Corporation Actuk.finance.yahoo.com - March 20 at 5:51 PMSample Preparation in Genomics, Proteomics, and Epigenomics Global Market Report 2023: Increased R&D Spending in Developing Economies Boosts Sectorbenzinga.com - March 14 at 11:50 PMEpigenomics AG: Revocation of admission to the Prime Standard (sub-segment of the regulated market with additional post-admission obligations)uk.finance.yahoo.com - March 10 at 8:11 AMPersonalized Medicine and Epigenomics Market Capitalizing on Market Growth: Essential Insights from Our Latest Research Reportmarketwatch.com - February 21 at 9:27 AMEpigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynskiuk.finance.yahoo.com - January 27 at 2:57 PMEQS-News: Epigenomics AG: Resignation of Supervisory Board Chairman Heino von Prondzynskimarkets.businessinsider.com - January 27 at 2:57 PMEQS-News: Pareto Securities AS publishes buy recommendation for Epigenomics AG sharemarkets.businessinsider.com - December 23 at 7:49 AMEQS-Adhoc: Epigenomics AG: Further raise of earnings guidance for the current fiscal year 2022markets.businessinsider.com - December 21 at 9:05 AMEQS-Adhoc: Epigenomics Releases Performance Data on Next Generation Testmarkets.businessinsider.com - December 14 at 10:03 AMEpigenomics Releases Performance Data on Next Generation Testuk.finance.yahoo.com - December 14 at 1:27 AMEQS-News: Epigenomics Releases Performance Data on Next Generation Testmarkets.businessinsider.com - December 14 at 1:27 AMEQS-News: Epigenomics Licenses Protein Biomarker Technology for Blood-based Colorectal Cancer Testmarkets.businessinsider.com - December 14 at 1:27 AMEpigenomics Reports Third Quarter 2022 Earningsyahoo.com - November 12 at 6:06 AMEQS-Adhoc: Epigenomics AG: Raise of earnings guidance for the current fiscal year 2022 due to currency gains and lower study costsmarkets.businessinsider.com - September 19 at 8:20 AMEpigenomics Initiates prospective multi-center clinical trial for “Next-Generation” blood-based colorectal cancer testuk.finance.yahoo.com - September 19 at 3:20 AMEQS-News: Epigenomics Initiates prospective multi-center clinical trial for Next-Generation blood-based colorectal cancer testmarkets.businessinsider.com - September 19 at 3:20 AMDGAP-Adhoc: Epigenomics AG: Capital reduction planned at a ratio of 4 : 1markets.businessinsider.com - September 9 at 4:12 PMEpigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktGuk.finance.yahoo.com - August 15 at 4:10 AMDGAP-News: Epigenomics AG: Notice of Loss pursuant to Sec. 92 par. 1 AktGmarkets.businessinsider.com - August 15 at 4:10 AMDGAP-News: Epigenomics AG Reports Financial Results for the First Six Months of 2022markets.businessinsider.com - August 10 at 2:38 PMEpigenomics AG Reports Financial Results for the First Quarter of 2022uk.finance.yahoo.com - May 11 at 5:38 AMDGAP-News: Epigenomics AG Reports Financial Results for the First Quarter of 2022markets.businessinsider.com - May 11 at 5:38 AMGlobal Personalized Medicine and Epigenomics Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028marketwatch.com - March 30 at 12:29 PMDGAP-News: Epigenomics AG Reports Financial Results for Fiscal Year 2021markets.businessinsider.com - March 24 at 4:21 AMEPGNY After-Hours Quotesnasdaq.com - January 14 at 8:43 PMEPGNY Real-Time Quotesnasdaq.com - January 6 at 7:25 AMDGAP-News: Epigenomics AG publishes financial results for the first nine months 2021markets.businessinsider.com - November 10 at 8:55 AMEpigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 millionuk.finance.yahoo.com - September 13 at 8:24 AMEpigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidanceuk.finance.yahoo.com - August 17 at 5:34 PM Get Epigenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for EPGNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better. Click here to find out that this 8,788% cryptocurrency is. EPGNY Media Mentions By Week EPGNY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPGNY News Sentiment▼0.000.46▲Average Medical News Sentiment EPGNY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPGNY Articles This Week▼00▲EPGNY Articles Average Week Get Epigenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for EPGNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BIAFW News IZOZF News MBGNF News MEDD News STRRP News WUXIF News WUXAY News TGIFF News FFNTF News ABSCF News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:EPGNY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epigenomics AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
